Zoetis (ZTS) Receives EC Approval For Simparica Trio In Dogs
Zacks Investment Research | Sep 23, 2019 12:36AM ET
Zoetis, Inc. (NYSE:ZTS) announced that the European Commission (EC) has granted marketing authorization to Simparica Trio (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with or at risk from mixed external and internal parasitic infestations.
An approval was in the cards as the Committee for Medicinal Products for Veterinary Use had given a positive opinion on the same in July.
The marketing authorization for Simparica Trio was based on the results of veterinary patient studies conducted in eight countries. The active ingredients of Simparica Trio are sarolaner, which is active against fleas and ticks; moxidectin, effective against heartworm, lungworm and some intestinal worms; and pyrantel embonate, effective against gastrointestinal nematodes (hookworms and roundworms).
The approval will give veterinarians a new choice for the treatment of mixed external and internal parasitic infestations. Moreover, the convenience of a once-monthly chewable tablet assures dog owners of continuous protection.
Zoetis expects to launch Simparica Trio in the EU in the first quarter of 2020.
The approval should strengthen the company’s market-leading parasiticide portfolio for companion animals. Meanwhile, regulatory reviews are also underway in the United States, Canada, Australia, Brazil and Japan, with further submissions expected in China and Mexico this year.
Per the company, the global canine parasiticides market is worth more than $4 billion and the largest therapeutic category in medicines for dogs.
The FDA earlier approved ProHeart 12 (moxidectin), the industry’s only once-yearly injection to prevent heartworm disease in dogs aged 12 months or older.
Zoetis’ stock has surged 46.8% year to date compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.